Save on Alglucosidase Alfa with Coupons, Discounts & Savings Programs

Alglucosidase Alfa is available as a 5 mg/mL solution.

Alglucosidase Alfa is an enzyme replacement therapy used to treat Pompe disease.

Alglucosidase Alfa is an enzyme replacement therapy. It replaces an enzyme (protein) that helps the body break down a large sugar called glycogen. People with Pompe disease aren’t able to break down glycogen because they’re either missing that enzyme or the enzyme doesn’t work. So glycogen can build up in the body and cause problems, especially in the muscles. Alglucosidase Alfa replaces the enzyme, which allows the body to break down glycogen and use it for energy.

The recommended dosage of Alglucosidase Alfa is 20 mg/kg body weight administered every 2 weeks as an intravenous infusion.

Alglucosidase Alfa is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Alglucosidase Alfa:

• Infants:
• Rash
• Fever
• Hives
• Flushing
• Cough
• Fast breathing
• Fast heart rate
• Children and adults:
• Excessive sweating
• Hives
• Chest discomfort
• Muscle twitching

Serious side effects are rare with Alglucosidase Alfa. Contact your healthcare provider immediately if you experience any of the following.

• Serious allergic and skin reactions: hives, rash, blisters, skin reddening, swelling of the lips or tongue, difficulty breathing

• There are no major drug interactions listed for Alglucosidase Alfa. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking

Various FDA-approved generic manufacturers

It is not known if Alglucosidase Alfa will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking Alglucosidase Alfa. Patients and their caregivers should be informed that a registry for patients with Pompe disease (the Pompe Registry) has been established in order to better understand the variability and progression of Pompe disease, and to continue to monitor and evaluate long-term treatment effects of Alglucosidase Alfa. The Pompe Registry will also monitor the effect of Alglucosidase Alfa on pregnant women and their offspring [see Use in Specific Populations (8)]. Patients and their caregivers are encouraged to participate in the Pompe Registry and advised that their participation is voluntary and may involve long-term follow-up. For more information regarding the registry program call 1-800-745-4447.

• Lumizyme
• Myozyme